FDA Warns Hims Over Ads About Compounded Weight-Loss Drugs

Core Insights - The FDA issued warning letters to numerous drug companies, including Hims & Hers, for "false or misleading claims" about their products [1] - This action occurred shortly after President Trump signed an order aimed at regulating direct-to-consumer drug advertising [1] Company Summary - Hims & Hers is among the companies that received warning letters from the FDA [1] - The letters demand corrections to the claims made about their products [1] Industry Summary - The FDA's crackdown reflects a broader regulatory effort to ensure truthful advertising in the pharmaceutical industry [1] - The timing of the warning letters coincides with new regulatory measures introduced by the government [1]